G
Gavin Dabrera
Researcher at Public Health England
Publications - 103
Citations - 8727
Gavin Dabrera is an academic researcher from Public Health England. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 19, co-authored 73 publications receiving 2760 citations. Previous affiliations of Gavin Dabrera include University of Birmingham & Yahoo!.
Papers
More filters
Journal ArticleDOI
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
Jamie Lopez Bernal,Nick Andrews,Charlotte Gower,Eileen Gallagher,Ruth Simmons,Simon Thelwall,Julia Stowe,Elise Tessier,Natalie Groves,Gavin Dabrera,Richard H. Myers,Colin Campbell,Gayatri Amirthalingam,Matt Edmunds,Maria Zambon,Kevin E. Brown,Susan Hopkins,Meera Chand,Mary Ramsay +18 more
TL;DR: The B.617.1.2 variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Coronavirus disease 2019 (Covid-19), has contributed to the development of the disease.
Journal ArticleDOI
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
Nick Andrews,Julia Stowe,Freja C M Kirsebom,Samuel E. Toffa,T S Rickeard,Eileen Gallagher,Charlotte Gower,Meaghan Kall,Natalie Groves,Anne Marie O’Connell,David Simons,Paula Blomquist,Asad Zaidi,S. Nash,Nurin Iwani Binti Abdul Aziz,Simon Thelwall,Gavin Dabrera,R. Myers,Gayatri Amirthalingam,Saheer E. Gharbia,Jeffrey C. Barrett,Richard Elson,Shamez N Ladhani,Neil M. Ferguson,Maria Zambon,Colin Campbell,Kevin K. Brown,Susan Hopkins,Meera Chand,Mary Ramsay,Jamie Lopez Bernal +30 more
TL;DR: Primary immunization with two doses of ChAdOx1 nCoV-19 or BNT162b2 vaccine provided limited protection against symptomatic disease caused by the omicron variant, but that protection waned over time.
Journal ArticleDOI
Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England.
Erik M. Volz,Swapnil Mishra,Meera Chand,Jeffrey C. Barrett,Robert Johnson,Lily Geidelberg,Wes Hinsley,Daniel J. Laydon,Gavin Dabrera,Áine O'Toole,Roberto Amato,Manon Ragonnet-Cronin,Ian Harrison,Ben Jackson,Cristina V. Ariani,Olivia Boyd,Nicholas J. Loman,Nicholas J. Loman,John T. McCrone,Sónia Gonçalves,David Jorgensen,Richard M. Myers,Verity Hill,David K. Jackson,Katy A. M. Gaythorpe,Natalie Groves,John Sillitoe,Dominic P. Kwiatkowski,Seth Flaxman,Oliver Ratmann,Samir Bhatt,Samir Bhatt,Susan Hopkins,Axel Gandy,Andrew Rambaut,Neil M. Ferguson +35 more
TL;DR: In this paper, the authors show that changes in VOC frequency inferred from genetic data correspond closely to changes inferred by S gene target failures (SGTF) in community-based diagnostic PCR testing.
Journal ArticleDOI
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study
Tommy Nyberg,Neil M. Ferguson,Seth Flaxman,Wes Hinsley,Meaghan Kall,Paula Blomquist,N. A. Aziz,Kattie Harman,Sebastian Funk,Meera Chand,Azra C. Ghani,Shaun R. Seaman,Daniela De Angelis,S. Nash,H. Webster,Nick Andrews,Jamie Lopez Bernal,Samir Bhatt,Asad Zaidi,Erik M. Volz,Nur Adilah Abdul Aziz,Sam Abbott,Russell Hope,Andre Charlett,Gavin Dabrera,Anne M. Presanis,Simon Thelwall +26 more
TL;DR: The risk of severe outcomes following SARS-CoV-2 infection is substantially lower for omicron than for delta, with higher reductions for more severe endpoints and significant variation with age.
Posted ContentDOI
Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data
Erik M. Volz,Swapnil Mishra,Meera Chand,Jeffrey C. Barrett,Robert Johnson,Lily Geidelberg,Wes Hinsley,Daniel J Laydon,Gavin Dabrera,Áine O'Toole,Roberto Amato,Manon Ragonnet-Cronin,Ian Harrison,Ben Jackson,Cristina V. Ariani,Olivia Boyd,Nicholas J. Loman,John T. McCrone,Sónia Gonçalves,David Jorgensen,Richard M. Myers,Verity Hill,David K. Jackson,Katy A. M. Gaythorpe,Natalie Groves,John Sillitoe,Dominic P. Kwiatkowski,Cog-Uk,Seth Flaxman,Oliver Ratman,Samir Bhatt,Susan Hopkins,Axel Gandy,Andrew Rambaut,Neil M. Ferguson +34 more
TL;DR: The SARS-CoV-2 lineage B.7, now designated Variant of Concern 202012/01 (VOC) by Public Health England, originated in the UK in late Summer to early Autumn 2020 as mentioned in this paper.